Professor Philip Morris – New Financial Transparency Arrangements Between Doctors and Drug Companies

Prof-Philip-Morris-GCMA-photo

Professor Philip Morris

In early 2015 the Australian Consumer and Competition Commission (ACCC) authorized a new Code of Conduct for Medicines Australia (representing the larger drug companies in Australia but not generic makers). This 18th Code Edition now includes making public all payments to doctors who speak at drug company events, payments for work on company advisory boards, and the monetary equivalent of gifts from companies to doctors for overseas and local travel, accommodation, conference registration fees and other forms of hospitality.

This move to greater transparency started back in 2009 and culminated this year with the adoption of many of the elements of the US Physician Payment Sunshine Act. Not included in the ACCC authorized Code is payments for food and drink below $120 per person. Payments associated with industry funded research trials are also not included. The payments will be published for individual doctors on a six-monthly basis on drug company websites accessible to the public.

Doctors are informed the payments will be reported and the doctor can check the payments are correct before publication. The reporting is voluntary for the year 2016 but becomes mandatory from 2017. From then on doctors not wishing to be reported would need to refuse to accept pharmaceutical company offers. Privacy concerns have been managed by making sure all doctors know that accepting these payments or gifts will result in publication of the amounts.

These changes to the Code were hard fought and controversial initially. They have been introduced to overcome perceived or potential conflict of interest concerns when substantial payments (or payments in kind) are made by drug companies to doctors and are kept hidden from public view. It is possible that the financial relationship between the doctor and the company could bias or influence the use or prescribing of pharmaceutical products. This is especially relevant given the pharmaceutical industry targets key doctor opinion leaders for these payments or gifts. read more

Prof Philip Morris, New financial transparency arrangements between doctors and drug companies, DrPhilMorris.com, 1 November 2015

Advertisements

About IMVAlliance.org

An international network of military veterans, families and friends affected by the health impacts of the neurotoxic antimalarial drug, mefloquine.
This entry was posted in Advocacy, Clinical Drug Trials, Media and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s